Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

Novartis knocks Pfizer off sales leader board

Swiss firm takes US giant’s crown as diversification programme and pipeline come to fruition

- PMLiVE

Mylan swoops in on Perrigo with $30bn offer

Comes amid a swarm of deals for both companies in recent years

Roche Basel Switzerland

Trials of Roche’s new blindness candidate now underway

Lampalizumab in phase III for age-related maculardegeneration

- PMLiVE

Celgene name Gerald F. Masoudi as executive VP

Will take up the role of executive VP, general counsel and corporate secretary

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

Avastin approved for cervical cancer in EU

Was approved for the same indication in the US last summer

- PMLiVE

Top biotech firms saw sales jump in 2014

But rate of growth slowing from the past five years according to new analysis

Shire Basingstoke

Shire pitching at adult ADHD product launch in 2017

Will have to first trial formulation in children to appease FDA

Turkey: Identifying the Growth Drivers

Published in eye for pharma 3 April by Marc Yates

Inizio

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

Bristol-Myers Squibb (BMS) building

BMS buys into gene therapy with $1bn uniQure alliance

US firm on a deal spree in 2015 as it racks up yet another collaboration

Can Cinderella save us?

UK government warns over antibiotic resistant deaths

Cabinet Office document says the next 20 years is a crucial period for creating new medicines

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links